Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Relief Therapeutics Holdings AG

< Previous 1 2 3 Next >
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Tickers RLFTF
Relief Reports that U.S. Collaboration Partner Announced Second Favorable Safety Report for ZYESAMI(TM) (RLF-100TM/aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Life-Threatening COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Reports Half-Year 2021 Results and Provides Corporate Update
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Tickers RLFTF
Relief's Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic(TM) Technology
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE(R) KRUNCH in Germany and Italy
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Tickers ACER
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers RLFTF
Relief Therapeutics Announces CHF 15 Million Private Placement
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers RLFTF
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers RLFTF
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.